ARS Cash from 2010 to 2026

SPRY Stock   10.03  0.36  3.72%   
ARS Pharmaceuticals Cash yearly trend continues to be fairly stable with very little volatility. Cash is likely to outpace its year average in 2026. Cash is the total amount of money in the form of currency that ARS Pharmaceuticals has in its possession. This includes all bills, coins, and funds in bank accounts. View All Fundamentals
 
Cash  
First Reported
2019-12-31
Previous Quarter
51.5 M
Current Value
59.6 M
Quarterly Volatility
126.1 M
 
Covid
 
Interest Hikes
Check ARS Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ARS Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 67.5 K, Gross Profit of 82.8 M or Other Operating Expenses of 111.4 M, as well as many indicators such as Price To Sales Ratio of 9.81, Dividend Yield of 0.0 or PTB Ratio of 3.76. ARS financial statements analysis is a perfect complement when working with ARS Pharmaceuticals Valuation or Volatility modules.
  
Build AI portfolio with ARS Stock
Check out the analysis of ARS Pharmaceuticals Correlation against competitors.
For more information on how to buy ARS Stock please use our How to Invest in ARS Pharmaceuticals guide.
The evolution of Cash for ARS Pharmaceuticals provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how ARS Pharmaceuticals compares to historical norms and industry peers.

Latest ARS Pharmaceuticals' Cash Growth Pattern

Below is the plot of the Cash of ARS Pharmaceuticals over the last few years. Cash refers to the most liquid asset of ARS Pharmaceuticals, which is listed under current asset account on ARS Pharmaceuticals balance sheet and usually includes currency, coins, checking accounts, and not deposited checks received from ARS Pharmaceuticals customers. The amounts must be unrestricted with restricted cash listed in a different ARS Pharmaceuticals account. It is the total amount of money in the form of currency that a company has in its possession. This includes all bills, coins, and funds in bank accounts. ARS Pharmaceuticals' Cash historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in ARS Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Cash10 Years Trend
Slightly volatile
   Cash   
       Timeline  

ARS Cash Regression Statistics

Arithmetic Mean43,352,500
Geometric Mean31,202,543
Coefficient Of Variation109.87
Mean Deviation30,698,882
Median20,160,000
Standard Deviation47,633,116
Sample Variance2268.9T
Range200.5M
R-Value0.52
Mean Square Error1775.5T
R-Squared0.27
Significance0.03
Slope4,868,452
Total Sum of Squares36302.6T

ARS Cash History

202670.2 M
202558.4 M
202450.8 M
202371 M
2022210.5 M
202160.1 M
202024.5 M

Other Fundumenentals of ARS Pharmaceuticals

ARS Pharmaceuticals Cash component correlations

About ARS Pharmaceuticals Financial Statements

ARS Pharmaceuticals investors use historical fundamental indicators, such as ARS Pharmaceuticals' Cash, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in ARS Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Cash58.4 M70.2 M
Cash And Short Term Investments361.1 M379.2 M
Change In Cash-18.1 M-17.2 M
Free Cash Flow11.7 M12.3 M
Begin Period Cash Flow81.6 M65.2 M
Total Cashflows From Investing Activities-95.5 M-90.7 M
Other Non Cash Items-1.6 M-1.5 M
Total Cash From Operating Activities12.2 M12.8 M
Total Cash From Financing Activities83.3 M56 M
End Period Cash Flow58.4 M70.2 M
Other Cashflows From Financing Activities83.3 M87.4 M
Other Cashflows From Investing Activities-6.8 M-6.4 M
Cash And Cash Equivalents Changes135.4 M120.4 M
Cash Flows Other Operating-2.2 M-2.3 M
Free Cash Flow Yield 0.01  0.02 
Operating Cash Flow Per Share 0.14  0.13 
Free Cash Flow Per Share 0.12  0.13 
Cash Per Share 2.92  1.85 
Capex To Operating Cash Flow 0.04  0.04 
EV To Operating Cash Flow 64.56  67.79 
EV To Free Cash Flow 67.36  70.73 
Price To Operating Cash Flows Ratio 67.94  71.33 
Price To Free Cash Flows Ratio 70.88  74.43 
Cash Ratio 1.95  1.85 
Cash Conversion Cycle(40.67)(38.64)
Operating Cash Flow Sales Ratio 0.17  0.18 
Free Cash Flow Operating Cash Flow Ratio 1.10  1.09 
Cash Flow Coverage Ratios 290.31  304.83 
Price Cash Flow Ratio 67.94  71.33 
Cash Flow To Debt Ratio 290.31  304.83 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for ARS Stock Analysis

When running ARS Pharmaceuticals' price analysis, check to measure ARS Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ARS Pharmaceuticals is operating at the current time. Most of ARS Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of ARS Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ARS Pharmaceuticals' price. Additionally, you may evaluate how the addition of ARS Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.